HIV Vaccines: A Brief Overview

Lema, Diego; García, Alexis; Sanctis, Juan B. De

doi:10.1111/sji.12184

Cited by 25 publications

(20 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ren antigorputzak, aipatutako gune kritiko hauetara zehazki zuzenduta daude [31]. Antigorputz hauek, infekzioa gertatu eta zenbait urtera agertu ohi dira; horrek esan nahi du birusekin batera ko-eboluzionatzen dutela antigorputzek [32].…”

Section: Gibaren Aurkako Txertoaren Bilaunclassified

“…Tximinoetan adibidez, ikusi izan da SIV indargabetuan oinarritutako txertoa tximinoei jaioberrian emanez, epe luzean zenbaitek HIESa garatzen zutela [36]. Izan ere, erretrobirusaren mutazio tasa altua dela eta, eboluzionatu eta berriro ere birus patogeniko bilaka daiteke [31].…”

Section: Gibaren Aurkako Txerto Motakunclassified

“…Esaterako, oso garrantzitsua da B eta T linfozitoen erantzuna pizteko eta mantentzeko zein baldintzak bete behar diren ulertzea. Esaterako, elitezko kontrolatzaileen inguruko ikerketa sakona egin behar da, tratamendurik jaso gabe birusarekin bizitzen diren indibiduo hauek dituzten berezitasunak ulertzeko [31,54].…”

Section: Ondorioakunclassified

See 2 more Smart Citations

GIBaren aurkako txertoaren bila

Torralba¹,

Goikoetxea²,

Apellániz

2017

EKAIA

View full text Add to dashboard Cite

Laburpena: GIB birusa, giza historian zehar gertatu den pandemiarik hilgarrienetariko baten eragilea da, HIESa alegia. Nahiz eta azken urteetan HAART terapia antirretrobiralari esker heriotza tasa asko murriztu den, infekzio berrien kopurua etengabe emendatzen ari da. Hori dela eta, badirudi pandemiari azkenik amaiera eman ahal izateko txerto prebentibo baten garapena izan daitekeela jokaera eraginkorrena. Hala ere, birusak garatu dituen estrategia natural desberdinek eta immunizazioz sortu nahi diren antigorputz neutralizatzaileen ezaugarri bereziek oso zaila egiten dute infekziotik babestuko lukeen txertoaren garapena. RV144 entsegu klinikoaren eraginkortasun apalek eta espektro zabaleko antigorputz neutralizatzaileekin immunizazio pasiboz lorturiko emaitzek iradokitzen dute hurbilago gaudela txerto eraginkor baten garapena lortzetik. Orain arte hainbat txerto mota erabili diren arren, emaitza onik ez da lortu. Hala ere, sakon aztertzen ari da bai immunogeno naturalen egitura, bai immunogenoak ezagutzen dituzten antigorputzen egitura, eta badirudi, besteak beste, ikerketa horiek bide berriak irekiko dituztela txerto berrien diseinuan. Hitz gakoak: GIB, txertoa, antigorputz neutralizatzaileak, Env fusio-glukoproteina.Abstract: HIV is the causative agent of one of the most lethal pandemics in human history, AIDS. Although in recent years HAART therapy has considerably reduced death rate, new infections keep arising. Therefore, a preventive vaccine remains the most promising tool to end the pandemic. However, the virus has developed many natural strategies to evade the immune system and, moreover, the special characteristics of the neutralizing antibodies that a vaccine aims to elicit, makes vaccine design extremely challenging. The efficiency of the RV144 clinical trial and the promising results obtained by passive immunization with broadly neutralizing antibodies suggest that the objective of obtaining an effective vaccine is closer. Until now, a myriad of vaccine strategies have been attempted but the expected results have not been yet ob-EKAIA 32.indd 7 EKAIA 32.indd 7

show abstract

Section: Gibaren Aurkako Txertoaren Bilaunclassified

Section: Gibaren Aurkako Txerto Motakunclassified

See 1 more Smart Citation

GIBaren aurkako txertoaren bila

Torralba¹,

Goikoetxea²,

Apellániz

2017

EKAIA

View full text Add to dashboard Cite

show abstract

“…However, despite almost 30 years of efforts, an HIV vaccine is still lacking and only one of the four HIV vaccines tested in efficacy trials [3,4] has provided some evidence of low and transient (60% at 12 months but 31% at 42 months) protection from acquisition of infection in a lowrisk population [5]. New trials are being designed to reproduce and further improve this vaccine efficacy [6].…”

Section: Introductionmentioning

confidence: 99%

Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine

Cafaro¹,

Tripiciano²,

Sgadari³

et al. 2015

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

“…Among these clinical trials, only six candidate vaccines have achieved clinical efficacy. These six vaccines include VAX004, VAX003, Phambali, HVTN505 and RV144 [18].…”

Section: Development Of An Hiv Vaccine: a Difficult Challengementioning

confidence: 99%

Efficacy Trials and Progress of HIV Vaccines

Asif¹,

Irshad²

2017

J Cell Sci Ther

View full text Add to dashboard Cite

Discovery of HIV as causative agent of AIDS let to the belief that a vaccine for AIDS will be available shortly but was not that easy, and it took more than 30 years of hard laboratory and clinical work toward HIV vaccine development. Efficacy trials of RV144 and their results revealed that HIV vaccine is accomplishable. Clinical trials for developing bNAbs has monoclonal antibodies and to increase its half-life are also underway to achieve a proper HIV vaccine. In this review article, we see that how these efficacy trials are highlighting HIV vaccine concepts in clinical development. Therapeutic vaccines are proving to be a functional cure toward HIV treatment and progress is ongoing in such HIV vaccine development which will attack HIV before it fuses with cell and cause infection thus preventing AIDS. So, in near future it will be possible to cure HIV and bring an end to this epidemic.

show abstract

HIV Vaccines: A Brief Overview

Cited by 25 publications

References 102 publications

GIBaren aurkako txertoaren bila

GIBaren aurkako txertoaren bila

Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine

Efficacy Trials and Progress of HIV Vaccines

Contact Info

Product

Resources

About